Organisation paid for research Program year 2024 Source: CMS Open Payments

Clarkston Skin Research

Neither a doctor nor a teaching hospital

Research payments

$986,498

82 payments

Through program year 2024, Clarkston Skin Research is reported as receiving $986,498 in research payments, across 82 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $39,880 6
2023 Research $94,695 13
2022 Research $165,876 8
2021 Research $314,455 20
2020 Research $147,654 8
2019 Research $223,937 27

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eli Lilly and Company $399,123 26 payments
  2. Ucb SA $324,972 9 payments
  3. Sun Pharmaceutical Industries Inc. $99,631 11 payments
  4. Amgen Inc. $80,006 15 payments
  5. Bausch Health US, LLC $42,569 9 payments
  6. LEO Pharma AS $17,363 6 payments
  7. AbbVie, Inc. $8,728 1 payment
  8. E.R. Squibb & Sons, L.L.C. $7,666 2 payments
  9. Pfizer Inc. $6,440 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $319,368 6 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $230,737 7 payments
  3. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $88,829 8 payments
  4. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $67,199 2 payments
  5. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $44,036 2 payments
  6. Phase 2b study of Tezepelumab in Atopic Dermatitis. $42,287 8 payments
  7. Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $40,855 8 payments
  8. Ph2b_chronic urticaria $37,556 5 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $22,622 2 payments
  10. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $18,525 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record